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ABSTRACT
Objective: To estimate the cost-effectiveness of a systematic
one-off Chlamydia trachomatis (CT) screening program
including partner treatment for Dutch young adults.
Methods: Data on infection prevalence, participation rates,
and sexual behavior were obtained from a large pilot study
conducted in The Netherlands. Opposite to almost all previous
economic evaluations of CT screening, we developed a
dynamic Susceptible-Infected-Susceptible (SIS) model to esti-
mate the impact of the screening program on the incidence and
prevalence of CT in the population. SIS models are widely used
in epidemiology of infectious diseases, for modeling the trans-
mission dynamics over time. Subsequently, a predictive deci-
sion model was used to calculate the complications averted by
the screening program. Cost-effectiveness was expressed as the
net costs per major outcome averted (MOA) and was esti-
mated in the baseline analysis and in sensitivity analysis.
Results: The overall prevalence decreased from 1.79% to
1.05% as a result of the screening program directed at both
men and women. The program costs were mainly offset by
the averted costs, although not fully. Resulting net costs per
MOA were €373 in the baseline analysis. Sensitivity analysis
showed that partner treatment and sending a reminder are
important aspects improving cost-effectiveness. Additionally,
restricting the screening to women only was estimated to
save costs.
Conclusions: Our cost-effectiveness analysis shows that the
Dutch society has net to pay for the prevention of CT-
complications through screening young men and women.
One could argue although that €373 per MOA presents a
reasonable cost. A screening program consisting of screening
women only should always be adopted from a pharmacoeco-
nomic point of view. Our dynamic approach appreciates bet-
ter the speciﬁc characteristics of an infectious disease, such as
CT.
Keywords: Chlamydia trachomatis, cost-effectiveness analy-
sis, screening, transmission dynamics.
Introduction
Infections caused by the bacteria Chlamydia trachom-
atis (CT) are the most prevalent sexually transmitted
infections in industrialized countries, such as in the
Netherlands [1]. In women, 70% of these infections
remain asymptomatic, which increases the risk of
infecting others and may cause long-term complica-
tions. Among these complications are pelvic inﬂamma-
tory disease (PID), chronic pelvic pain (CPP), ectopic
pregnancy, and infertility [2–4]. Vertical transmission
from mother to child may lead to conjunctivitis and
pneumonia [5]. These serious complications are
accompanied by major individual and societal costs;
total costs for sexually transmitted diseases (STDs) in
The Netherlands have been estimated at €25 million,
with CT being the most important Dutch STD cur-
rently (http://www.rivm/nl/kostenvanziekten).
Screening programs have become more feasible
with the introduction of sensitive DNA detection
methods, such as the polymerase chain reaction (PCR)
test on urine, and the highly effective single-dose azi-
thromycin treatment [6,7]. Active case ﬁnding and
early treatment can prevent the development of seque-
lae and the transmission of the disease in the popula-
tion. CT screening of young persons, especially
women, is recommended in several countries including
Sweden and the United States [8,9]. In The Nether-
lands, the issue whether or not to implement a national
screening program is under discussion, as is currently
the case in other countries such as the UK.
When considering implementing a screening pro-
gram cost-effectiveness is an important factor to take
into account. Many cost-effectiveness analyses have
evaluated the costs and health outcomes of both
opportunistic and systematic screening programs with
and without partner treatment [10–17]. Except three
studies [16–18], all of these cost-effectiveness analyses
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were based on static models. Nevertheless, because CT
is a transmissible infectious disease the spread of the
disease over time in the population should ideally be
taken into account. Consequently, more valid results
may be expected if a dynamic model is used instead of
a static one [19].
In this article we used a dynamic model to estimate
the cost-effectiveness of a one-off systematic CT
screening program including subsequent (partner)
treatment among 15- to 29-year-old men and women.
Our approach builds on a previous model that was
published in this journal [12]. In particular, the static
approach presented previously to evaluate partner
treatment is extended into a dynamic one. Addition-
ally, our approach builds on data gathered within the
context of a recently performed pilot study on CT
screening in The Netherlands [20]. These data involve,
for example, participation in the screening, asympto-
matic infections detected, sexual behavior and a cost
analysis. Summarizing, our current analysis combines
an epidemiologic and cost analysis of a Dutch screen-
ing program into a model to estimate downstream
health gains and related savings on health-care costs.
Methods
In this section we elaborate on the data and the model
used for the cost-effectiveness analysis. The model con-
sists of a dynamic epidemiologic part and an economic
part. The epidemiologic part was used for estimating
the impact of the screening program on the incidence
and prevalence of CT in the population. The economic
part addresses the averted complications and averted
costs and the cost analysis of the screening program.
Both models were linked by using the output of the
epidemiologic part as input for the economic analysis
to estimate cost-effectiveness.
Data
Data were used from a pilot study of systematic one-
off CT screening in four regions in The Netherlands
organized via the Municipal Public Health Services
[20]. The study population consisted of 21,000 males
and females from the general population aged 15 to
29 years. The sampling method is comprehensively
described elsewhere [20]. The selected persons received
a package by mail containing a urine sampling kit.
Returned urine samples were pooled by ﬁve and tested
for the presence of chlamydial DNA by means of PCR.
Persons who tested CT positive received a referral let-
ter for a health-care provider. It was recommended to
treat current partners together with the index case.
Partner referral for investigation and/or treatment for
all partners of the previous 6 months was recom-
mended and registered. A prevalence of CT infection
of 2% was found [20]. For calibrating our model (see
Dynamic Epidemiologic Model) screening test preva-
lence was corrected for sensitivity and speciﬁcity of the
CT test, assumed at 98.8% and 99.9%, respectively
[21]. This procedure rendered a corrected prevalence
of 1.79%.
Dynamic Epidemiologic Model
We used a deterministic SIS model, in which individu-
als who are Susceptible can be Infected after which
they return to the Susceptible class on recovery. SIS
models are widely used in exploring the transmission
dynamics of infectious diseases [22]. The model is
described in detail in the Appendix. The model
describes a heterosexual population of 100,000 man
and women with a sex ratio 1:1 and a uniform age dis-
tribution over 15 to 29 years. People (15-year-olds)
who enter the model exactly balance the people (30-
year-olds) who leave the model. The population was
divided according to gender, level of sexual activity
(core and noncore), and condition (susceptible, symp-
tomatically infected or asymptomatically infected).
Persons in the pilot study who reported sexual inter-
course with two or more different partners in the last
half year were denoted as the core group although the
others are denoted as the noncore group. As a conse-
quence of the stratiﬁcation by sexual activity an
assumption about the mixing of the subpopulations is
required. We used the mixing structure to calibrate the
model on the corrected prevalence allowing all struc-
tures from full proportionate mixing to full preferred
mixing within one’s own sexual activity group only
(see Appendix) [23,24].
We assumed that before the implementation of the
screening program the infection has reached endemic
equilibrium. So, in absence of any perturbations the
incidence and prevalence are not changing over time
(Appendix). The parameter values used in the epide-
miologic model are shown in Table 1 [25–28]. These
values were derived both from literature and the pilot
study.
The systematic screening program targeting 15- to
29-year-old males and females containing treatment
of index cases and (ex-)partners of the last 6 months
was integrated in the epidemiologic model at time,
t = 0 (Appendix). Of all eligible persons 47% of the
women and 33% of the man sent in urine [20]. Of the
positive index cases 90% were treated. Moreover,
43% of the partners of male index cases (80% of
them current, 20% of them ex) were treated (con-
ﬁrmed) compared with 51% of partners of female
index cases (98% of them current, 2% of them ex)
[30]. Effectiveness of azithromycin was assumed to be
95% [7]. Furthermore, in the baseline analysis, we
assumed that only half of the complications were
averted in those cases averted as a direct result of the
screening program at t = 0 [31]. Because the infections
were already present before t = 0 they already could
have caused damage.
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Economic Model
Progression of disease. A progression-of-disease tree
was used to calculate the complications in the presence
and absence of the screening program, related to the
incidences of asymptomatic infections in both cases.
Figure 1 reﬂects this progression tree for women and
the accompanying probabilities that describe the dis-
ease progression of asymptomatic infected persons.
The progression tree for men was simply assuming
epididymitis in 2% of asymptomatically infected per-
sons without any further complications. Symptomatic
CT infections (cervicitis and male urethritis) were
assumed to be treated without complications and no
further progression of disease was taken into account
[17–19]. Without screening every asymptomatically
infected person enters the progression-of-disease tree,
with screening the entrance is limited according to the
effectiveness of the screening speciﬁed above. The
Table 1 Parameter values used in the epidemiologic model
Parameter Value Reference(s)
Number of people*
N1 (men, core) 0.056 Ntotal† PILOT
N2 (women, core) 0.041 Ntotal† PILOT
N3 (men, noncore) 0.444 Ntotal† PILOT
N4 (women, noncore) 0.459 Ntotal† PILOT
Average number of partners per individual per half year*
a1 (men, core) 4.23 PILOT
a2 (women, core) 3.89 PILOT
a3 (men, noncore) 0.66 PILOT
a4 (women, noncore) 0.79 PILOT
Transmission probability
Transmission probability without condom use 0.68 [21]
qc (transmission probability, core) 0.41
qn (transmission probability, noncore) 0.55
Symptomatic infections
pm proportion symptomatic infections male 0.5 [22]
pf proportion symptomatic infections female 0.3 [22]
Recovery rate (per year)
va (asymptomatic infections) 1.0 [23]
vs. (symptomatic infections) 12.0 [24]
“Inﬂux/efﬂux” rate (per year)
μ 1/15 Model assumption
*Rounded ﬁgures; as partnerships closely balance (estimated total number of male contacts are 52,992 for Ntotal; female 52,210), no adjustment for using these ﬁgures in the
model is required [29]; †Ntotal = 100,000.
Figure 1 Tree for the disease progression of asymptomatically infected persons (IVF, in vitro fertilization), probabilities used in the baseline analysis are
indicated.
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probabilities, except the probability of developing PID,
were obtained from a review of the current literature
[12,16]. The probability of developing a PID after
being infected was estimated at 0.20 [12,16,31,32].
Because the probabilities of being pregnant and desir-
ing future pregnancy are age-dependent, the probabil-
ities of pregnancy-related sequelae of CT infection are
age-dependent as well. The probabilities of vertical
transmission resulting in neonatal conjunctivitis and
pneumonia and of having an ectopic pregnancy were
estimated using overall birth rates in The Netherlands
[33]. In particular, overall birth rates were interpreted
indicating the proportion of women being pregnant
during a year. For the probability of being identiﬁed as
infertile only the birth rates of the ﬁrst children were
used. For this purpose, birth rates of ﬁrst children were
interpreted as indicating the proportion of women
having a pregnancy wish. Future outcomes averted
were discounted at a rate of 4% per year in the base-
line analysis. Complications in newborn and devel-
oped PID were assigned to the year of infection. It was
assumed that CPP occurs 5 years after PID.
Averted  costs. Because the complications of a CT
infection may involve the use of medical resources and
the loss of productivity time, monetary beneﬁts were
achieved by the screening program. Our analysis was
performed using the societal perspective: both the
averted direct medical costs (irrespective of reimburse-
ment issues) and the indirect costs of production losses
were included in the analysis as shown in Table 2 [34].
The cost estimates were updated from the research pre-
viously published by Postma et al. in this journal [12],
by converting them to 2002 prices using gross domes-
tic product deﬂators [35]. Future costs were dis-
counted at a rate of 4% per year in the baseline
analysis according to the Dutch guidelines for pharma-
coeconomic research [34].
Cost analysis of screening. Program costs that were
taken into account consist of the costs associated with
screening, subsequent (partner) treatment and the
implementation of the program. All program costs
were derived from the pilot study. Estimated costs of
€660,000 for the implementation of the program were
based on the workload reported by the participating
agencies adjusted for population size. These costs do
not depend on the prevalence. The screening and
treatment costs do depend on the prevalence. The
whole study population received a package by mail
containing a urine sampling kit, introductory letter
and information leaﬂet on CT with a total cost of
€3.50 a piece. Nonresponders received a reminder
(67,000) after 6 weeks at a cost of €0.68. All packages
returned (41%) yielded €1.22 because of potential
reuse of the package. Urine samples were pooled by
ﬁve and tested by PCR with a cost of €12 per test
including labor and laboratory costs. All participants
received their test result by mail at a cost of €0.49 and
those tested positive also received a referral letter for
the health-care provider (extra €0.10). It was assumed
that 90% of the positive cases visited a general prac-
titioner, consisting of both direct (€17.50) and indirect
costs, and received an azithromycin prescription at a
cost of €13.55 (inclusive the prescription fee for the
pharmacist). In the pilot study there were different
ways of treating the (ex-)partner. Here it was assumed
that current partners were treated together with the
index by the same health-care provider, resulting in an
extra prescription. Ex-partners received a referral let-
ter for the health-care provider and were assumed to
visit a GP. All screening-related costs are listed in
Table 3.
Table 2 Estimates of undiscounted direct and indirect medical
costs used as inputs for the cost-effectiveness model (2002
euros; source: [12]), proportions of patients using inpatient and
outpatient care are indicated between brackets
Complication* Direct costs Indirect costs†
Symptomatic PID
Inpatient treatment (0.25) 4,085 292 (672)
Outpatient treatment (0.75) 70 139 (320)
CPP
Inpatient treatment (0.30) 3,460 292 (672)
Outpatient treatment (0.70) 614 139 (320)
Ectopic pregnancy 3,040 896 (896)
Infertility investigation
Inpatient treatment (0.20) 2,420 224 (224)
Outpatient treatment (0.80) 841 303 (303)
In vitro fertilization 3,138 421 (421)
Neonatal conjunctivitis 41 Not applicable
Neonatal pneumonia
Inpatient treatment (0.10) 16,882 Not applicable
Outpatient treatment (0.90) 98 Not applicable
Epididymitis
Inpatient treatment 2,123 286 (891)
Outpatient treatment 86 143 (445)
Male urethritis 46 10 (30)
Cervicitis 46 8 (15)
*Probabilities of inpatient and outpatient treatment are in parentheses [11]; †Indirect
costs are shown for persons aged 15 to 24 (for persons aged 25 to 29 indirect costs
are in parentheses).
CPP, chronic pelvic pain; PID, pelvic inﬂammatory disease.
Table 3 Estimated direct costs of the screening program by
category in 2002 euros (for one category of indirect costs and
savings on returned packages see text)
Costs
Implementation of the program 660,000
Package 3.50
Sending a reminder 0.68
PCR test 12
Sending results 0.49 (0.59*)
General practitioner visit* 17.50
Treatment (azithromycin)* 7.55
Prescription fee* 6
*For persons with a positive test only.
PCR, polymerase chain reaction.
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Modeling Cost-Effectiveness
The dynamic epidemiologic and the economic models
were linked together by using the output of the epide-
miologic model in terms of annual symptomatic and
asymptomatic CT-cases as input for the economic
model. In the economic model these incidences were
followed with respect to complications (Fig. 1) and the
related resource use and costs (Table 2) in both situa-
tions investigated in the incremental analysis: no
screening versus screening. In the latter case also the
screening costs (Table 3) were included. The differ-
ences between both options resulted in the net costs
(savings) for screening and the averted complications
through screening, combined in the incremental cost-
effectiveness ratio in euros per disease outcome averted
(i.e., health gain).
In particular, we expressed cost-effectiveness as the
net costs per major outcome averted (MOA) and as net
cost per PID averted [36–38]. Symptomatic PID, CPP,
ectopic pregnancy, infertility, and neonatal pneumonia
were considered major outcomes and were aggregated
into one ﬁgure. Because several major outcomes may
occur in one patient, additionally PID was analyzed as
separate outcome because this complication is condi-
tional for many others (Fig. 1). Cost-effectiveness is
presented in a baseline analysis as well as a sensitivity
analysis. The parameter values introduced above are
used in the baseline analysis. A period of 10 years was
chosen for analyzing the impact of the screening pro-
gram on the CT incidence and prevalence in the pop-
ulation. Complications and related costs for cases in
these 10 years were included in the model, despite the
fact that complications may take place beyond this
period. A period of 10 years was chosen to fully
acknowledge the dynamics of our approach within a
still reasonable time frame to produce plausible results.
Beyond 10 years one may assume that various inﬂu-
encing factors have signiﬁcantly changed in the mean-
time, rendering our results potentially invalid.
A univariate sensitivity analysis was performed for
all uncertain parameters to test the robustness of the
outcomes of the analysis. The baseline parameter
values for probability of PID, recovery rate of asymp-
tomatic infections, percentage complications averted a
t = 0, PCR test costs and discount rate were varied
over plausible ranges (as derived from previous
research [12,16]) to explore the impact of different
parameter values on the results.
A limitation of the SIS model used is the difﬁculty to
model the regular partner treatment (both before and
after t = 0). Generally, regular partner treatment con-
cerns asymptomatically infected current partners of
symptomatic index cases who visit a general practi-
tioner. These partners are subsequently treated and
recover quickly. In the baseline analysis regular partner
treatment was not modeled (recovery rate va equals 1
for all asymptomatic cases). In the sensitivity analysis
we did investigate the impact of including regular part-
ner treatment  on  the  cost-effectiveness  by  assuming
a higher recovery rate for asymptomatic infections
throughout the model (va = 1.2) as a result of this reg-
ular partner treatment.
Moreover, the following scenarios were investi-
gated: 1) screening women only; 2) absence of any
partner treatment; 3) not sending a reminder; and 4)
treating 56% (85% current, 15% ex) and 68% (95%
current, 5% ex) of the partners of, respectively, the
male and female index cases (these percentages include
conﬁrmed and probable partner treatments in the pilot
study CT [20, 30]).
Results
The steady state prevalence’s by sexual activity and
gender obtained with the dynamic model closely agree
with the corrected prevalences. For the male core
group we obtained a corrected prevalence and a model
prevalence of 5.1% and 6.3%, respectively, whereas
for the noncore group the prevalences (1.0%) exactly
match. Regarding females, we obtained a corrected
prevalence of 7.2% and a model prevalence of 8.4%
for the core group and a corrected prevalence of 1.7%
and a model prevalence of 1.4% for the noncore
group. The mixing structure to obtain the estimated
overall prevalence of 1.79% was close to proportion-
ate mixing. The exact mixing structure is provided in
the Appendix.
Baseline Analysis
The one-off screening program reduces the CT preva-
lence in the whole population as shown in Fig. 2. The
overall prevalence drops from 1.79% before to 1.05%
after the screening (at t = 0), after which it takes a long
period to reach the steady state prevalence again.
Indeed, if after the intervention there would be no mix-
ing between the different sexual activity groups any-
more, eradication of CT in the noncore groups is
achieved (results not shown). Ergo, a certain level of
Figure 2 Chlamydia trachomatis prevalence in the whole population
before (steady state) and after the intervention (t = 0).
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mixing is required between core and noncore groups
to sustain CT-transmission in the population.
The investment in screening and (partner) therapy is
estimated at €1,212,778 for a population of 100,000
men and women. These program costs are mainly off-
set by the €1,039,308, which is averted over 10 years
by the one-off screening program. So, the screening
program is estimated to cost €373 per MOA or €274
per PID averted (Table 4).
Figure 3 speciﬁes the distribution of the averted
costs by disease category. Approximately one-third of
the averted costs are a direct result of the prevention of
PID. Furthermore, costs of with ectopic pregnancies
(18%) and CPPs (17%)—that are indirectly related to
PID—and those of symptomatic infections (20%) are
substantially responsible for the total costs averted. As
can be derived from the ﬁgure, MOAs (averted symp-
tomatic PIDs, CPPs, ectopic pregnancies, infertilities,
and neonatal pneumonias) are responsible for approx-
imately three-quarters of the averted costs. Further-
more, over a 10-year period the one-off screening
program in our modeled population of 100,000 per-
sons leads to the prevention of 634 cases of PID, 125
cases of CPP, 86 ectopic pregnancies, 53 infertilities,
75 neonatal complications, 52 cases of epididymitis
and 3896 symptomatic infections.
Sensitivity Analysis
The results of the univariate sensitivity analysis are
presented in Table 4. The progression rate to PID is an
important model parameter. Varying the rate from
0.10 to 0.25 has a large inﬂuence on the outcomes.
Reducing the risk to 0.10 results in a 218% increase in
the net costs and in, respectively, 48% and 50% reduc-
tion in the number of MOAs and PIDs averted. Con-
versely, assuming a PID risk of 0.25 the program is
estimated cost-saving.
By assuming a recovery rate of 1.2 for asympto-
matic infections to indirectly model regular partner
treatment, the screening program is estimated even
more cost-effective (€106 per MOA and €78 per PID
averted) than in baseline. Relatively small changes are
seen when changing the discount rate to 3% or 5% as
is common in other countries or when the health ben-
eﬁts are not discounted at all. Varying the percentage
of complications averted as a direct result of the
screening program (t = 0) between 0 and 100%, and
doubling the test costs only had limited inﬂuence on
Table 4 Outcomes of the incremental analysis in the baseline and sensitivity analysis for a population of 100,000 persons (costs in
2002 euros)
No screening Screening 
Costs 
complications
Major outcomes
(PIDs) Screening costs
Costs 
complications
Major outcomes
(PIDs)
Cost/MOA
(cost/PID averted)
Baseline analysis 2,754,059 1217 (1658) 1,212,778 1,714,750 752 (1024) 373 (274)
Sensitivity analysis
Probability PID 0.15 2,259,408 927 (1244) 1,212,778 1,409,126 573 (768) 1023 (763)
Probability PID 0.10 1,764,758 638 (829) 1,212,778 1,103,502 394 (512) 2261 (1741)
Probability PID 0.25 3,248,709 1506 (2073) 1,212,778 2,020,374 930 (1281) −27 (−20)
va = 1.2 3,242,786 1424 (1940) 1,212,778 2,084,756 906 (1235) 106 (78)
Complications averted at t = 0, 0% 2,754,059 1217 (1658) 1,212,778 1,770,163 782 (1066) 527 (386)
Complications averted at t = 0, 100% 2,754,059 1217 (1658) 1,212,778 1,659,337 721 (983) 238 (175)
Only direct costs 2,246,111 1217 (1658) 1,204,093 1,397,804 752 (1024) 765 (562)
Cost PCR test €24 2,754,059 1217 (1658) 1,308,658 1,714,750 752 (1024) 579 (425)
Discounting 3% 2,942,713 1298 (1727) 1,212,778 1,838,089 805 (1071) 219 (165)
Discounting 5% 2,584,433 1143 (1594) 1,212,778 1,604,006 704 (981) 529 (379)
Discounting effects 0% (costs 4%) 2,754,059 1354 (1768) 1,212,778 1,714,750 757 (1035) 291 (237)
Screening females only 2,754,059 1217 (1658) 669,077 2,035,271 895 (1220) −154 (−113)
Without reminder 2,754,059 1217 (1658) 1,141,108 1,899,135 834 (1137) 748 (549)
No partner treatment 2,754,059 1217 (1658) 1,208,660 1,992,425 876 (1194) 1312 (962)
Partner treatment (male index: 
56%, female index: 68%)
2,754,059 1217 (1658) 1,214,189 1,619,892 709 (967) 158 (116)
MOA, major outcome averted; PCR, polymerase chain reaction; PID, pelvic inﬂammatory disease; va, recover rate for asymptomatic infections.
Figure 3 Percentage distribution of costs by
disease category averted by the screening
program. CPP, chronic pelvic pain; PID, pelvic
inﬂammatory disease.
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the outcomes as well. Nevertheless, excluding indirect
costs of production losses almost doubled the cost-
effectiveness ratio.
Partner treatment as well as sending a reminder can
be considered as cost-saving interventions within the
screening program. Both cause a large decrease in the
total net costs and a large increase in the number of
major outcomes and PIDs averted. Finally, restricting
the screening only to women the program is estimated
cost-saving.
Discussion and Conclusion
Application of our dynamic model shows that the costs
of the one-off systematic screening program exceed the
beneﬁts of averted health care under baseline assump-
tions; society has net to pay for the prevention of CT
complications. Cost-effectiveness was estimated at
€373 per MOA and €274 per PID averted in the base-
line analysis. We estimated that the overall prevalence
would initially decrease to 1.05% as a result of the
screening program. The core group maintains infection
in the population and as a result of somewhat
restricted mixing between core and noncore groups the
infection takes more than 10 years to reach again the
previous steady state prevalence in the population as a
whole (Fig. 2).
Our sensitivity analysis has illustrated that both
partner treatment and sending a reminder are cost-
saving activities within the screening program; these
activities improve overall cost-effectiveness. The
importance of partner referral has been demonstrated
before [12]. Obviously, it depends on the number of
responders whether or not sending a reminder is cost-
effective. Also, the sensitivity analysis revealed limited
impact for varying the discount rate. This may be
explained by the facts that: 1) the screening costs are
insensitive to discounting because they occur at the
beginning of the analysis only; and 2) the vast majority
of complications (costs) are averted in the ﬁrst 5 years
of our 10-year time frame (Fig. 2).
There are several limitations of our study. One gen-
eral limitation inherent to mathematical models is that
the validity of the results strongly depends on the pre-
cision of the parameter estimates [39]. Data on sexual
behavior and the screening program were obtained
from the pilot study whereas data on the natural
course of a CT infection were derived from clinical tri-
als (Table 1). The sensitivity analysis shows that the
risk of developing PID has a large impact on the cost-
effectiveness of the screening program. Unfortunately,
different studies have quantiﬁed the risk of PID differ-
ently [31, 32, 40], so there is still a debate on the exact
risk. Because this parameter value has such a large
inﬂuence on the outcomes future research is required
to exactly determine the risk of developing PID. Fur-
thermore, the model assumes a population with a uni-
form age and sex distribution where no migration
occurs and also the assumption of a stable-steady state
prevalence over time may not hold. Nevertheless, obvi-
ously any model should be a simpliﬁcation of reality to
an acceptable degree. Also, we implicitly assumed that
no selection occurs in participating in the screening,
that is, prevalence is similar in those participating and
those not participating in the screening. Finally, we
note that our model renders the prevalence found in
the investigated population, which does obviously not
guarantee that also the predicted prevalence is valid.
External validation of the model is needed, however,
data are yet lacking.
Our SIS model differs from a network model, as
developed, for example, by Kretzschmar et al. [16,41].
Ours is deterministic and population-based, whereas
the one developed by Kretzschmar et al. is stochastic
and individually based. The advantage of the network
approach is that it is very detailed and potentially very
realistic. For instance, a network approach would eas-
ily allow for modeling recurrent and persistent infec-
tion, which is not included in our current approach.
Furthermore, partner notiﬁcation can explicitly be
modeled and it is possible to assume an increased risk
of complications in those who have been reinfected.
Nevertheless, the data requirements are much more
extensive for such a network model, in particular
regarding data on sexual behavior. Unfortunately, lim-
itations deﬁnitely apply to the availability of accurate
data on sexual behavior hampering the use of stochas-
tic network models. We dealt with this scarce availa-
bility of accurate data on sexual behavior by
calibrating the model with the mixing matrix on the
corrected test prevalence.
The design of the SIS model confronted us with a
difﬁculty to model the regular partner treatment (i.e.,
before and after t = 0). In the sensitivity analysis we
indirectly assessed the inﬂuence of including regular
partner treatment on the cost-effectiveness. It is shown
that an increase in the recovery rate for asymptomatic
infections decreases the costs per MOA and per PID
averted. So, if partner treatment is current practice the
screening program becomes more cost-effective. Fur-
thermore, our estimate of cost-effectiveness may be too
conservative for another reason. The impact of CT on
the susceptibility for other STDs (e.g., HIV) was not
taken into account; CT increases the susceptibility for
other STDs [42].
The use of a dynamic model—such as the SIS
model—to estimate the cost-effectiveness of a CT
screening program has major advantages. Until now, a
static approach has been the standard for determining
the cost-effectiveness of CT screening programs. Nev-
ertheless, as with all infectious diseases, it is very
important to take the transmission dynamics of CT
into account to not (hugely) overestimate the cost-
effectiveness ratio and underestimate attractiveness of
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the program. In particular, a static approach would not
consider beneﬁts and health gains beyond the immedi-
ate effect of the screening. Of our averted costs and
major outcomes, 93% and 94% are beyond this imme-
diate effect, respectively.
Policy impact of our application of the dynamic
approach may be that CT screening is more and more
seen as a cost-effective intervention. Inclusion of the
dynamic effects of such a screening greatly enhances
the health-economic proﬁle of this intervention. Cur-
rently, in The Netherlands, interventions are valued
with respect to the “ofﬁcial” cutoff point for cost-
effectiveness/cost-utility at €20,000 per life-year
gained or quality-adjusted life-year (QALY) [43]. A
crude assessment of the cost-utility of our analysis is
possible using recently published QALY weights for
the US situation: 0.90 (during 4 weeks) for sympto-
matic infection, 0.65 (during 11 days) for symptomatic
PID, 0.60 (during 5 years) for CPP, 0.58 (during
4 weeks) for ectopic pregnancy and 0.82 (during the
rest of life until age 50) for infertility [18]. Inclusion of
these estimates in our model with baseline assumptions
renders a cost-utility below €1000/QALY, obviously
warranting adoption given the above speciﬁed thresh-
old. Obviously, this crude assessment is only indicative
and requires further research to validate QALY
weights for the Dutch population.
In conclusion, we have shown that the prevention
of one major outcome as a result of the screening pro-
gram costs €373 for the Dutch situation. One could
argue that this is a reasonable cost for preventing a
major outcome (e.g., infertility). There exist several
other prevention programs where society has net to
pay for the prevention of complications due to infec-
tious diseases [44,45]. A screening program consisting
of screening women only and subsequent partner treat-
ment should always be adopted from a pharmacoeco-
nomic point of view because it is a cost-saving activity
(Table 3). Nevertheless, cost-effectiveness is not the
only aspect to consider before implementation, others
being, for example, ethical, budgetary, and organiza-
tional aspects.
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Appendix
SIS Model
The population was divided into four different groups
according to gender and sexual activity level. Further-
more, each different group can be divided into three
different classes according to the condition (sympto-
matically infected, asymptomatically infected or sus-
ceptible). Consequently, this results in a division into
12 different classes. These 12 different classes can be
described by a system of 12 nonlinear ordinary differ-
ential equations. The three general equations are given
by:
The demographic and epidemiologic parameters in
these equations are:
t = time,
Isi = number of symptomatically infected in group i;
Iai = number of asymptomatically infected in group i;
Si = number of susceptible in group i;
λij = contact rate, average number of contacts resulting
in infection per unit time of an infective in group j with
persons in group i. The contact rate is deﬁned by:
mijajqj;
mij = the proportion of partners by an average infective
of group j in group i;
aj = average number of partners per unit time of per-
sons in group j;
qj = transmission probability with condom use taken
into account;
pi = proportion symptomatic infections (gender-
speciﬁc);
νs = per capita recovery rate for symptomatic
infections;
νa = per capita recovery rate for asymptomatic
infections;
μ = the “inﬂux/efﬂux” rate.
The values used for these parameters in the model
are shown in Table 1. It was assumed that qj = qc if
i = 1 and j = 2, and qj = qc otherwise (see Table 1).
Because the population is stratiﬁed by sexual activ-
ity it is required to make an assumption about the mix-
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ing of the subpopulations. We adapted the so-called
proportionate mixing assumption; a commonly made
assumption that states the subpopulation mixes ran-
domly, but weighted with their sexual activity [22–24].
For  proportionate  mixing  holds  that  mij = aiNi/A,
where in general A = . Whereas a member of
the core group may be more likely to have sexual inter-
course with a member of the core group the pro-
portionate mixing assumption is not completely
reasonable. So, we used a mixing matrix M = [mij] that
is C times the mixing matrix for proportionate mixing
and C-1 times the mixing matrix for solely mixing
within the two sexual activity classes. The last matrix
is ﬁlled solely with zero’s and one’s.
Steady State
Before the screening program we assumed a steady
state so that there was no time dependence in the inci-
dence and prevalence. In other words the 12 differen-
tial equations were set to zero: dIsi/dt = 0, dIas/dt = 0,
and dSi/dt = 0. Subsequently, these equations were
solved to obtain the prescreening equilibrium number
of symptomatically infected, asymptomatically
infected and susceptible. We varied the mixing struc-
ture to calibrate on the estimated real overall preva-
lence in the pilot study (1.79%). The best ﬁt was
acquired with a C of 0.86, which gave the mixing
matrix M as shown below:
Screening Program
For the entire population it was assumed that screen-
ing and partner treatment took place at one and the
same point in time (t = 0). In general, the number
infected is decreased as a result of the screening pro-
gram as shown by: It = 0 = Isteady state − (A + B) where A
and B represent the efﬂux as a result of screening and
partner referral, respectively. First, the number recov-
ered as a result of screening (A) can be represented as:
Isteady state × proportion screened × test sensitivity × pro-
portion treated × effectiveness azithromycin. As an
example we provide the efﬂux due to the screening
program in the male, noncore, and symptomatically
infected class (Is1): A = 28.65 × 0.334 × 0.988 ×
0.9 × 0.95 = 8.08.
Nevertheless, the estimation of the efﬂux as a result
of partner referral is much more complex. People can
only be treated as a result of partner referral as a part-
ner (index) in the last half year is tested positive. Pos-
itive tested index cases consist of true positives and
false positives. The partners (index cases) can be
divided into three categories: partners before infection,
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partners after infection, and the infector who transmit-
ted the infection. We return to the example to clarify
the above. An asymptomatic infected person on aver-
age got infected half a month ago because the recovery
rate is 12. The probability that the infector was
symptomatically infected is 0.04 and that she was
asymptomatically infected was 0.96. The probability
that the infector still is infected at t = 0 is 23/24 for
asymptomatically infected infectors and 1/2 for symp-
tomatically infected infectors. So, the overall probabil-
ity of the infector still being infected at t = 0 is
0.04 × 23/24 + 0.96 × 1/2, that is, 0.94. The number
of partners after being infected is 0.35 (= a1/12) of who
0.14 (= 0.35 × qc) are infected at t = 0. Finally, the
number of partners before getting the infection is 2.88
(= a1 − a1/12 − 1). The probability for them still being
infected at t = 0 is 0.04, which directly results from the
mixing matrix and the prevalence. Summarizing, the
above results in 1.21 (0.94 + 0.14 + 2.88 × 0.04)
infected and 3.03 (= a1/2 − 1.21) noninfected partners
per symptomatically infected male member of the core
group. Subsequently, the number of true positives
(= number of partners in the past half year who are
infected × test sensitivity × proportion screened of
opposite sex) and the number of false positives
(= number of partners in the past half year who are not
infected × [1 – test speciﬁcity] × proportion screened
of opposite sex) are estimated to be 0.55 and 0.00,
respectively. Because current partners were epidemio-
logically treated together with the index and ex-
partners were tested before treating the efﬂux as a
result of partner referral (B) becomes: (28.65 − 28.65
× 0.33) × ([0.55 + 0.00] × proportion partners treated
× [proportion current partners × proportion treated +
test sensitivity × proportion ex-partners]). In this
example B is estimated to be 4.63, which results in an
It = 0 of 15.94 what means that 12.71 symptomatically
infected male members of the core group are cured as
a direct result of the screening program and return to
the susceptible class.
